Privia Health Group, Inc. (NASDAQ:PRVA) Receives $30.42 Average Price Target from Brokerages

by · The Cerbat Gem

Shares of Privia Health Group, Inc. (NASDAQ:PRVA – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the fifteen ratings firms that are presently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $30.4167.

PRVA has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Privia Health Group in a research note on Monday. Canaccord Genuity Group raised their price objective on shares of Privia Health Group from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, November 12th. BMO Capital Markets started coverage on shares of Privia Health Group in a research note on Thursday, November 13th. They issued an “outperform” rating and a $30.00 price objective for the company. Stephens reiterated an “overweight” rating and set a $32.00 target price on shares of Privia Health Group in a research report on Thursday, December 4th. Finally, JPMorgan Chase & Co. raised their price target on shares of Privia Health Group from $32.00 to $33.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th.

Check Out Our Latest Stock Report on PRVA

Privia Health Group Stock Up 1.9%

PRVA opened at $24.13 on Wednesday. Privia Health Group has a twelve month low of $18.77 and a twelve month high of $26.51. The company has a fifty day moving average of $24.32 and a 200-day moving average of $22.87. The stock has a market cap of $2.97 billion, a PE ratio of 185.63, a price-to-earnings-growth ratio of 4.04 and a beta of 0.83.

Privia Health Group (NASDAQ:PRVA – Get Free Report) last issued its quarterly earnings results on Tuesday, June 7th. The company reported $0.10 EPS for the quarter. Privia Health Group had a net margin of 0.89% and a return on equity of 2.52%. The business had revenue of $213.61 million for the quarter. Sell-side analysts anticipate that Privia Health Group will post 0.14 EPS for the current fiscal year.

Insider Transactions at Privia Health Group

In other news, Director Matthew Shawn Morris sold 13,647 shares of the firm’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $25.01, for a total value of $341,311.47. Following the completion of the sale, the director directly owned 68,188 shares in the company, valued at $1,705,381.88. This trade represents a 16.68% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO David Mountcastle sold 23,887 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $25.03, for a total value of $597,891.61. Following the transaction, the chief financial officer directly owned 172,909 shares in the company, valued at approximately $4,327,912.27. This trade represents a 12.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 10.70% of the stock is owned by corporate insiders.

Institutional Trading of Privia Health Group

Several hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Privia Health Group by 5.3% during the third quarter. Vanguard Group Inc. now owns 12,098,933 shares of the company’s stock worth $301,263,000 after buying an additional 607,447 shares during the last quarter. Durable Capital Partners LP increased its position in shares of Privia Health Group by 1.8% during the third quarter. Durable Capital Partners LP now owns 11,691,685 shares of the company’s stock worth $291,123,000 after acquiring an additional 203,842 shares in the last quarter. State Street Corp raised its holdings in shares of Privia Health Group by 1.5% in the 2nd quarter. State Street Corp now owns 4,171,069 shares of the company’s stock worth $95,935,000 after acquiring an additional 61,853 shares during the last quarter. Van Berkom & Associates Inc. lifted its position in Privia Health Group by 30.1% in the 3rd quarter. Van Berkom & Associates Inc. now owns 3,774,565 shares of the company’s stock valued at $93,987,000 after acquiring an additional 873,344 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Privia Health Group by 6.3% during the 2nd quarter. Geode Capital Management LLC now owns 2,655,569 shares of the company’s stock valued at $61,086,000 after purchasing an additional 158,521 shares during the last quarter. Institutional investors and hedge funds own 94.48% of the company’s stock.

About Privia Health Group

(Get Free Report)

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.

Featured Stories